Pipeline Review for Gliosarcoma, H1 2018 - Evaluates Therapeutics Based on Mechanism of Action, Drug Target, Route of Administration and Molecule Type - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Jun 6, 2018--The “Gliosarcoma - Pipeline Review, H1 2018” report has been added to ResearchAndMarkets.com’s offering.
The pipeline guide provides a snapshot of the global therapeutic landscape of Gliosarcoma (Oncology).
The pipeline guide reviews pipeline therapeutics for Gliosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
The pipeline guide reviews key companies involved in Gliosarcoma (Oncology) therapeutics and enlists all their major and minor projects.
The pipeline guide evaluates Gliosarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
The pipeline guide reviews latest news related to pipeline therapeutics for Gliosarcoma (Oncology).
Key Topics CoveredIntroduction Gliosarcoma - Overview Gliosarcoma - Therapeutics Development Gliosarcoma - Therapeutics Assessment Gliosarcoma - Companies Involved in Therapeutics Development Gliosarcoma - Drug Profiles Gliosarcoma - Dormant Projects Appendix
Companies MentionedAbbVie Inc Agenus Inc Apexigen Inc Arog Pharmaceuticals Inc Bristol-Myers Squibb Co Celgene Corp DelMar Pharmaceuticals Inc DNAtrix Inc ERC Belgium SA Ipsen SA Kite Pharma Inc Merck & Co Inc Millennium Pharmaceuticals Inc NewLink Genetics Corp Northwest Biotherapeutics Inc Novartis AG Nuo Therapeutics Inc
For more information about this report visit https://www.researchandmarkets.com/research/jq6kf2/pipeline_review?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180606005510/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Brain Cancer Drugs
INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 06/06/2018 04:52 AM/DISC: 06/06/2018 04:52 AM